Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294. https://doi.org/10.1186/s12886-020-01554-2.
2. Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27:44–6.
3. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.
4. Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor? Ocul Immunol Inflamm. 2021:1–3.
5. Genentech. 2021. https://www.gene.com/media/press-releases/14935/2021-10-22/fda-approves-genentechs-susvimo-a-first-. Accessed 12 Nov 2021.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献